Aurobindo Pharma Gets USFDA Approval for Generic Tofacitinib Tablets
Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration to manufacture and market generic Tofacitinib tablets in 5 mg and 10 mg strengths. The drug is bioequivalent and therapeutically equivalent to Pfizer's Xeljanz tablets and will be produced at Aurobindo's subsidiary, APL Healthcare Unit IV. Tofacitinib is used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, with an estimated U.S. market size of approximately $494 million.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (75/100). Lens Score 35/100 — moderate-to-low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- thehindu— balanced framing, positive sentiment
- businessstandard— balanced framing, positive sentiment
AI Analysis
The articles present a straightforward business and regulatory update without political framing. Both sources focus on the approval and manufacturing details, reflecting a neutral corporate and healthcare industry perspective. There is no evident political bias or partisan interpretation in the coverage.
The tone across the articles is neutral to positive, emphasizing the regulatory approval and market opportunity. The coverage highlights the company's achievement and product details without emotional language or criticism, maintaining an informative and factual sentiment.
How 2 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.